RemedyRepack Recalls Valsartan 80 mg Tablets Due to Carcinogen Impurity
RemedyRepack Inc. is recalling Valsartan 80 mg tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient used to manufacture the product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a carcinogen impurity, which constitutes a significant health risk warranting a Severe rating under the rubric for significant injury/property-damage reports or high-risk contamination.
Plain-English summary
RemedyRepack Inc. is voluntarily recalling Valsartan 80 mg tablets, packaged in HDPE 90 cc bottles in cardboard trays. The recall is due to Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of a carcinogen impurity in the active pharmaceutical ingredient (API) used to manufacture the drug product.
The affected product is identified by NDC 61786-0791-19. The recall includes six specific lot numbers: B0335344-081717 (exp. 08/2018), B0363364-110917 (exp. 11/2018), B0391225-012218 (exp. 01/2019), B0408458-030618 (exp. 03/2019), B0384871-010318 (exp. 01/2019), and B0436862-051518 (exp. 05/2019). Each unit consists of 9 bottles of 90 tablets, totaling 810 tablets.
The product was distributed to three customers in Florida and Virginia. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the supplier or disposed of according to local regulations. Patients should consult their healthcare provider for alternative treatment options if they have been taking the affected medication.
The recalled product
- Product
- Valsartan 80 mg Tablet,s HDPE 90 cc bottles in cardboard trays, Rx Only, RemedyRepack, Inc., 625 Kolter Drive, Suite 4, Indiana, PA 15701, NDC 61786-0791-19
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot # B0335344-081717
- exp. date 08/2018 Lot # B0363364-110917
- exp. date 11/2018 Lot # B0391225-012218
- exp. date 01/2019 Lot # B0408458-030618
- exp. date 03/2019 Lot # B0384871-010318
- exp. date 01/2019 Lot # B0436862-051518
- exp. date 05/2019
Distribution
Part of a larger recall action
This product is one of 3 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · carcinogen impurity
See all →- SevereMacleods Pharma Recalls Losartan Potassium and Hydrochlorothiazide Tablets Due to Carcinogen
FDA (Drugs) · 2019-03-27
- SevereAurobindo Recalls Irbesartan Bulk Ingredient Due to Carcinogen Impurity
FDA (Drugs) · 2018-11-07
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12
Similar recalls
- SevereRemedyRepack Recalls Valsartan/HCTZ Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-08
- SevereBryant Ranch Recalls Valsartan 80 mg Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-08
- SevereAvKARE Recalls Valsartan Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-09-05
- SevereTorrent Pharma Recalls Valsartan Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-09-05
- SevereBryant Ranch Recalls Valsartan 320 mg Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-08
- SevereNorthwind Pharmaceuticals Recalls Valsartan 80mg Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-22